Enterprise Value
10.55B
Cash
976.7M
Avg Qtr Burn
N/A
Short % of Float
2.10%
Insider Ownership
1.06%
Institutional Own.
96.38%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INGREZZA (valbenazine) Details Huntington's disease, Dyskinesia | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Huntington's disease, Chorea | Approved Quarterly sales | |
INGREZZA (valbenazine) Details Huntington's disease, Chorea, Dyskinesia | PDUFA Approval decision | |
Valbenazine Details Neurological disorder, Dyskinesia , Cerebral Palsy | Phase 3 Data readout | |
Crinecerfont Details Congenital adrenal hyperplasia | Phase 3 Data readout | |
Valbenazine Details Psychiatric disorder, Schizophrenia | Phase 2 Data readout | |
NBI-1065846 Details Major depressive disorder | Phase 2 Data readout | |
NBI-921352 Details Focal Onset Seizures | Phase 2 Data readout | |
NBI-1117570 (Dual M1/M4 Agonist) Details Schizophrenia | Phase 1 Data readout |